Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TL011

Monoclonal antibody · Antagonist of CD20 (MS4A1) · developed by Teva Pharmaceutical Industries

Phase 1 Most advanced trial (none active)

TEVA Developer

1 Registered trials

What is TL011?

TL011 is a monoclonal antibody that binds CD20 on B cells. It is studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: CD20 (MS4A1)
Mechanism: Antagonist of CD20 (MS4A1)
Pathways: B cell apoptosis
Therapy area: Immunology
Developer: Teva Pharmaceutical Industries, Ltd. (TEVA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01123070	Phase 1	Rheumatoid Arthritis	Completed	TEVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Other drugs acting on MS4A1

AZD5492 Phase 1/2 Imvotamab Phase 1/2 Odronextamab Phase 2/3

More from Teva Pharmaceutical Industries

Omacetaxine Mepesuccinate FDA approved Laquinimod Phase 2 TV-1106 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TEVA page.

Follow TEVA, the company behind TL011

See TEVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TEVA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z